Thread by @jgalt485

businesswire.com/news/home/2022…

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced a new vaccine supply agreement with the U.S. government to support the continued fight against COVID-19.

Under the agreement, the U.S. government will receive 105 million doses (30 µg, 10 µg and 3 µg). This may include adult Omicron-adapted COVID-19 vaccines, subject to authorization from the U.S. Food and Drug Administration (FDA).

The doses are planned to be delivered as soon as late summer 2022 and continue into the fourth quarter of this year.
The U.S. government will pay the companies $3.2 billion upon receipt of the first 105 million doses. Under this agreement, the U.S. government also has

the option to purchase up to 195 million additional doses, bringing the total number of potential doses to 300 million.
“As the virus evolves, this new agreement will help ensure people across the country have access to vaccines that may provide protection against

current and future variants,” said Albert Bourla, Chairman and Chief Executive Officer, Pfizer.
“This agreement will provide additional doses for U.S. residents and help cope with the next COVID-19 wave. Pending regulatory authorization, it will also include

an Omicron-adapted vaccine, which we believe is important to address the rapidly spreading Omicron variant,” said Sean Marett, Chief Business and Chief Commercial Officer of BioNTech.
On June 25, 2022, Pfizer and BioNTech reported pivotal data demonstrating the safety,

tolerability and immunogenicity of two Omicron-adapted vaccine candidates. These data have been shared with regulators, including the FDA, and a request for U.S. Emergency Use Authorization is planned. The companies have begun manufacturing the Omicron-adapted vaccines

so that they can begin deliveries rapidly upon authorization or approval and subsequent recommendation by the U.S. Centers for Disease Control and Prevention’s (CDC), if received, and as directed by the U.S. government.
The Pfizer-BioNTech COVID-19 Vaccine,

which is based on BioNTech’s proprietary mRNA technology, was developed by both BioNTech and Pfizer. BioNTech is the Marketing Authorization Holder in the United States, the European Union, the United Kingdom, Canada and other countries,

and the holder of emergency use authorizations or equivalents in the United States (jointly with Pfizer) and other countries. Submissions to pursue regulatory approvals in those countries where emergency use authorizations or equivalent were initially granted are planned.

U.S. Indication & Authorized Use
Pfizer-BioNTech COVID-19 Vaccine is FDA authorized under Emergency Use Authorization (EUA) for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

in individuals 6 months of age and older.
Pfizer-BioNTech COVID-19 Vaccine is FDA authorized to provide:
Primary Series
a 3-dose primary series to individuals 6 months through 4 years of age
a 2-dose primary series to individuals 5 years of age and older

a third primary series dose to individuals 5 years of age and older with certain kinds of immunocompromise
Booster Series
a single booster dose to individuals 5 through 11 years of age who have completed a primary series with Pfizer-BioNTech COVID-19 Vaccine

a first booster dose to individuals 12 years of age and older who have completed a primary series with Pfizer-BioNTech COVID-19 Vaccine or COMIRNATY® (COVID-19 Vaccine, mRNA)
a first booster dose to individuals 18 years of age and older who have completed primary vaccination

with a different authorized or approved COVID-19 vaccine. The booster schedule is based on the labeling information of the vaccine used for the primary series
a second booster dose to individuals 50 years of age and older who have received a first booster dose of

any authorized or approved COVID-19 vaccine
a second booster dose to individuals 12 years of age and older with certain kinds of immunocompromise and who have received a first booster dose of any authorized or approved COVID-19 vaccine

Emergency uses of the vaccine have not been approved or licensed by FDA, but have been authorized by FDA, under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID 19) in individuals 6 months of age and older.

The emergency uses are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner.

INTERCHANGEABILITY
FDA-approved COMIRNATY® (COVID-19 Vaccine, mRNA) and the Pfizer-BioNTech COVID-19 Vaccine FDA authorized for Emergency Use Authorization (EUA) for individuals 12 years of age and older can be used interchangeably by a vaccination provider.

Donc pour résumer, #BidenIsAFailure compte à nouveau faire administrer au peuple américain des doses sans fin de "vaccin" anti covid 19 Pfizer (300 Mios de doses commandées en tout). Pour une soupe censée protéger contre Omicron et ses sous-variants, dont l'hyper contagiosité

n'a d'égal que leur caractère bénin. Pfizer destine ces doses à des enfants âgés de 6 mois et plus, comme à des adultes, avec des 1 ou 2 "boosters" prévus. L'EUA obtenue aux USA, sur la base des seules données fournies par Pfizer, sera suivie d'AMM conditionnelle dans l'UE.

La Hyène recommencera à commander 500 Mios de doses au moins. Le cirque continuera ... jusqu'à ce que les peuples refusent en masse la vaccination. Ce qui va arriver. Vous êtes prévenus. Résistez. Toute obéissance vous perdra.

@YvesPDB @JeanYvesCAPO @AllanicFabian @mmtchi @Medic4allHuman @papanours60 @BanounHelene @ChrisCottonStat @v_joron @Verhaeghe @PhilippeMurer @Don_Quichoute @andrebercoff @Poulin2012 @CaudeHenrion @Houdiakova @HigueroLucien @JuliaCerisi @BOROWSKIMIKE @MyriamHebuterne @_2019_nCoV